Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study
- 14 July 2011
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 23 (4) , 255-260
Abstract
Combination therapy is a common approach to psoriasis, aimed at improving clinical response and minimizing the risk of side effects. The aim of this pilot randomized open-label study was to evaluate the efficacy and safety of the combination of low-dose cyclosporine (CsA) with calcipotriol–betamethasone dipropionate (CBD) ointment in the treatment of psoriasis. Sixty patients with moderate-to-severe plaque psoriasis were randomized to receive CsA, 2 mg/kg/day, combined with CBD ointment (n = 30) or CsA, at the same daily dosage, in combination with an emollient (n = 30), for 8 weeks. The primary efficacy parameter was the Psoriasis Area and Severity Index (PASI) 75 response rate at 8 weeks. Combination therapy with CsA and CBD ointment was more effective than CsA and emollient treatment, with statistically significant results, particularly less itching after 4 and 8 weeks and PASI reduction at all post-baseline visits. Significantly more patients treated with CsA + CBD achieved the PASI 75 at 8th week (87% vs 37% in the CsA–emollient group; p = 0.0001). The efficacy results were paralleled by the investigator and patient's global assessment of disease severity at the end of study. Our results suggest that the addition of CBD ointment to low-dose CsA enhances clinical response and improves the risk/benefit ratio.Keywords
This publication has 18 references indexed in Scilit:
- Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgarisTherapeutics and Clinical Risk Management, 2008
- Efficacy Results of a 52-Week, Randomised, Double-Blind, Safety Study of a Calcipotriol/Betamethasone Dipropionate Two-Compound Product (Daivobet®/Dovobet®/Taclonex®) in the Treatment of Psoriasis VulgarisDermatology, 2006
- Update on the use of ciclosporin in immune-mediated dermatosesBritish Journal of Dermatology, 2006
- A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease SeverityDermatology, 2005
- The topical treatment of psoriasisClinical and Experimental Dermatology, 2005
- The use of ciclosporin in psoriasisJournal of Dermatological Treatment, 2005
- Calcipotriol/Betamethasone DipropionateAmerican Journal of Clinical Dermatology, 2004
- A New Calcipotriol/Betamethasone Formulation with Rapid Onset of Action was Superior to Monotherapy with Betamethasone Dipropionate or Calcipotriol in Psoriasis VulgarisActa Dermato-Venereologica, 2002
- Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized studyBritish Journal of Dermatology, 1999
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978